Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.
Lorenzo CastagnoliSimona CorsoAlma FranceschiniAlessandra RaimondiSara Erika BellomoMatteo DugoFederica MoranoMichele PrisciandaroSilvia BrichAntonino BelfioreAndrea VingianiMaria Di BartolomeoGiancarlo PruneriElda TagliabueSilvia GiordanoFilippo PietrantonioSerenella Maria PupaPublished in: Cellular oncology (Dordrecht) (2023)
Our findings indicate that cotargeting HER2 and FASN increase the benefit of anti-HER2 therapy representing a new opportunity for metabolically combating trastuzumab-resistant HER2+ GC.